Clinical trial NCT00753636: Parkinson's Disease Isradipine Safety Study
Official title: Phase II Safety and Tolerability of Isradipine (A Potential Neuroprotective Agent) in Patients With Parkinson's Disease- Stage II
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Parkinson's Disease
Keywords: Parkinson's disease
Isradipine
Neuroprotection
Lead sponsor: Northwestern University
Sponsor class: OTHER
Collaborators: name: Northwestern Memorial Hospital
First posted: 2008-09-16
Enrollment: 31
Sex: ALL
Minimum age (years): 30
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The objective of this study is to establish the safety and tolerability of isradipine, sustained release preparation in patients with PD. This study is a logical continuation of the project that is being completed now and is conducted in preparation to NIH submission of the pivotal study on the efficacy of this agent for neuroprotection in PD. This study is conducted in parallel with Dr. Surmeier's work on further development of the preclinical data. The focus of his work now is to establishing the correlation between the dose that demonstrated neuroprotective effect in animal model and the dose used for clinical practice.

Hypothesis 1: Patients with PD will be able to tolerate isradipine across the FDA recommended dose range. We expect 10% attrition due to hypotensive effect of the agent.

Hypothesis 2: Patients with PD and concomitant stable hypertension will be able to tolerate isradipine provided that the dose of the concomitant antihypertensive agent is adjusted based on the blood pressure reading.

Detailed description: Isradipine safety profile Isradipine, FDA approved for treatment of hypertension since 1990, has a well established data on its efficacy and safety in the hypertensive population (see package insert, Appendix 3). The side effect profile of isradipine is related to the primary mechanism of action of the agent as a vasodilator of the vascular smooth muscles and myocardium, and includes hypotension, bradycardia, weakness, and syncope. As per package insert, the most common adverse effects are headache (13.7% with active treatment versus 14% placebo), dizziness (7.3 vs 4.4) and peripheral edema as reflection of the vasodilatory effect which is dose dependent with incidence of about 3.5% at 5 mg, 8.7% at 10 mg and 8.5% at 20 mg. Of note the incidence of edema is substantially lower compared to CR preparation (9:13:36% for the respective doses). The other side effects include angina, asthenia, flushing, heart failure, and palpitations. According to the package insert, the adverse effects are usually not serious, dose dependent, and respond well to dose reduction or discontinuation of therapy. Isradipine has no effect on atrioventricular or sinoatrial conduction. The only absolute contraindications for isradipine are hypersensitivity to DHP compounds and hypotension defined as systolic blood pressure below 90 mm Hg. Until our studies, isradipine has not been tested in the PD population.

Eligibility criteria: Inclusion Criteria:

1. Patients with idiopathic Parkinson's disease age 30-75
2. Hoehn and Yahr stage \<2.5
3. PD duration less than 5 years
4. For the subjects treated with PD medications, the regimen has to be stable for \>1 month prior to enrollment

Exclusion Criteria:

1. Atypical Parkinsonian syndrome
2. Patients with history of stable hypertension treated with other antihypertensive agents will be allowed provided that the doses of concomitant anti HTN therapy can be reduced/adjusted during the study based on the BP readings. The number of concomitant antihypertensive agents should not exceed two. The dose of concomitant antihypertensive agents has to be stable for \> 1 month
3. Presence of orthostatic hypotension at the screening visit defined as \> 20 mmHg change in systolic BP and 10mm change in diastolic BP after 2 min of standing, or baseline BP \<90/60.
4. Presence of other medical conditions that in the opinion of the investigator will preclude safe use of the drug.
5. Presence of cognitive dysfunction as determined by MMSE score \<24
6. Failure to sign the informed consent
7. Inability to cooperate with the study procedures
8. Presence of motor fluctuations
9. History of bradycardia defined as heart rate \< 55
10. Women of childbearing potential who are not surgically sterilized have to use a reliable measure of contraception and have a negative urine pregnancy test at screening
11. Participation in other investigational drug trials within 30 days prior to screening
12. History of brain surgery for Parkinson's Disease.

Primary outcomes:
measure: Tolerability of Isradipine Based on the Number of Participants That Complete the Study
timeFrame: 1 year
Secondary outcomes:
measure: Safety of the Standard Titration Schedule in PD Population as Measured by the Number of Patients That Are Able to Increase the Dose to 20 mg Daily
timeFrame: 1 year
measure: Number of Participants That Tolerated Each Dose of Isradipine
timeFrame: 1 year
measure: Number of Participants That Tolerated Each Dose Level of Isradipine Between PD Patients Treated With Antihypertensive Agent and Not on Antihypertensive Agent
timeFrame: 1 year
measure: Number of Participants That Completed the Study at Each Dose Level of Isradipine
timeFrame: 1 year
measure: Change in Motor UPDRS Scores: Baseline vs. Final Visit
timeFrame: 12 weeks
measure: Pharmacokinetic Data - Mean Serum Concentration and Dosage Exposure Across the Dose Range of Isradipine
timeFrame: 1 year
Other outcomes:
Locations:
city: Chicago
country: United States
facility: 710 N. Lake Shore Dr.
state: Illinois
Study officials:
affiliation: Northwestern University
name: Tanya Simuni, M.D.
role: PRINCIPAL_INVESTIGATOR
References: